Shares of Omeros Co. (NASDAQ:OMER – Get Free Report) have earned an average rating of “Moderate Buy” from the five ratings firms that are currently covering the firm, MarketBeat Ratings reports. Two analysts have rated the stock with a hold recommendation, two have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $22.50.
A number of equities analysts have commented on the stock. Needham & Company LLC reissued a “hold” rating on shares of Omeros in a research note on Friday, January 17th. StockNews.com upgraded shares of Omeros from a “sell” rating to a “hold” rating in a research report on Thursday. Finally, D. Boral Capital restated a “buy” rating and set a $36.00 price target on shares of Omeros in a research report on Thursday, February 20th.
View Our Latest Stock Report on OMER
Hedge Funds Weigh In On Omeros
Omeros Trading Up 7.1 %
Shares of OMER opened at $8.42 on Friday. The stock has a 50-day moving average price of $8.80 and a 200-day moving average price of $7.15. The company has a market cap of $487.94 million, a PE ratio of -3.65 and a beta of 2.03. Omeros has a 12-month low of $2.61 and a 12-month high of $13.60.
About Omeros
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.
Read More
- Five stocks we like better than Omeros
- What Are the U.K. Market Holidays? How to Invest and Trade
- Rubrik Stock’s V-Bottom Reversal Signals a Major Rally Ahead
- How to Calculate Inflation Rate
- How Super Micro Computer Stock Is Defying the Market Sell-Off
- Value Investing: Is it a Good Strategy in 2022? (Hint: Always)
- AppLovin vs. HPE: Which Tech Stock Can Bounce Back Faster?
Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.